Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference
- SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference. Event: Jefferies Global Healthcare Conference, New York Fireside ChatDate: Thursday, June 5, 2025 Time: 12:50-1:20 PM ET A webcast of the event will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com.
- 05/28/2025
|
Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress
- Topline data from multiple Phase 2 studies expected throughout 2025 • Q2 readout from VTX3232 study in patients with early Parkinson's disease • H2 readout from VTX2735 study in patients with recurrent pericarditis • H2 readout from VTX3232 study in participants with obesity and cardiometabolic risk factors Cash, cash equivalents and marketable securities balance of $228.8M as of March 31, 2025 expected to fund planned operations into at least H2 2026 SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today reported first quarter financial results and highlighted recent pipeline and business progress. “Ventyx has established itself as the leader in discovery and development of NLRP3 inhibitors with two novel compounds, VTX3232 and VTX2735 progressing through Phase 2 trials in neurodegenerative, cardiovascular, and metabolic indications - disease states thought to be driven by pathologic activation of the NLRP3 inflammasome,” said Raju Mohan, PhD, President and Chief Executive Officer.
- 05/08/2025
|
Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists
- Appointment of seven recognized experts is validating for Ventyx's NLRP3 Program -- AD/PD™ 2025 provides helpful insights on potential next steps in Parkinson's disease SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, today announced the appointment of seven additional internationally-recognized scientists and clinicians to its Scientific Advisory Board (SAB): Mo Lamkanfi, PhD, Luke O'Neill, PhD, Ted Dawson, MD, PhD, Martin Pomper, MD, PhD, Antonio Abbate, MD, PhD, Paul Cremer, MD and Don Frail, PhD. The new SAB members have made vital discoveries in understanding the role of the NLRP3 inflammasome in neuro- and systemic inflammation, and are at the forefront of clinical development in neurodegenerative and cardiometabolic diseases.
- 04/01/2025
|
Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress
- Topline data readouts from multiple Phase 2 studies expected throughout 2025 VTX2735 in patients with recurrent pericarditis in H2 VTX3232 in participants with obesity and cardiometabolic risk factors in H2 VTX3232 biomarker study in patients with early Parkinson's disease in Q2 Cash, cash equivalents and marketable securities balance of $252.9M as of December 31, 2024 expected to fund operations into at least H2 2026 SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today reported fourth quarter and full year 2024 financial results and highlighted recent pipeline and business progress. “Heading into 2025, Ventyx has established itself as the leader in the field of NLRP3 inhibition having progressed two novel inhibitors, VTX3232 and VTX2735, into Phase 2 trials in neurodegenerative, cardiovascular, and metabolic indications.
- 02/27/2025
|
Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025
- Poster highlights robust, dose-dependent endoscopic response with VTX958 and reductions in key inflammatory markers Full analysis of Phase 2 results, including data from the 52-week treat-through LTE phase, is expected to inform development strategy and partnership opportunities for VTX958 SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that data from the Phase 2 trial of its TYK2 inhibitor VTX958 in Crohn's disease will be presented during the 20th Congress of the European Crohn's and Colitis Organisation (ECCO) being held in Berlin, Germany from February 19-22, 2025. “The Phase 2 data for VTX958 in Crohn's disease represent an important milestone for TYK2 inhibition in inflammatory bowel disease,” said Raju Mohan, PhD, Founder and Chief Executive Officer.
- 02/18/2025
|
Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
- SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, today announced that Company executives will participate in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference.
- 02/05/2025
|
Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio
- First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in H2 2025
- 01/14/2025
|
VENTYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ventyx Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
- NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ventyx Biosciences, Inc. (NASDAQ: VTYX) on behalf of long-term stockholders following a class action complaint that was filed against Ventyx on March 1, 2024 with a Class Period from October 21, 2021 to November 6, 2023. Our investigation concerns whether the board of directors of Ventyx have breached their fiduciary duties to the company.
- 12/10/2024
|
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
- SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences:
- 11/12/2024
|
Ventyx Biosciences: Ready To Escape "The Crash Cycle"
- Based on quatitative factors, Ventyx is similar to other issues I've rated here on Seeking Alpha that have outpaced the market. Because of its extremely low valuation and strong financials, I see obvious potential for Ventyx to outperform the market. Despite past troubles, management actions are addressing issues, though risks include volatility and the risk that drugs will not go commercial.
- 11/04/2024
|
VTYX Stock Rises on Strategic Equity Investment Deal With SNY
- Ventyx stock climbs 7% on signing a $27 million strategic investment agreement with Sanofi in exchange for granting exclusive rights to VTX3232.
- 09/24/2024
|
Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences
- On Monday, Sanofi SA SNY agreed to make a $27 million strategic investment in Ventyx Biosciences Inc VTYX.
- 09/23/2024
|
Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease
- SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that the first patient has been dosed in a Phase 2a trial of VTX3232 in patients with early Parkinson's disease.
- 09/06/2024
|
Ventyx Biosciences Announces Departure of Chief Financial Officer
- SAN DIEGO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Martin Auster, M.D. has departed from his role as Chief Financial Officer, effective August 30, 2024. Roy Gonzales, CPA, MBA, the Company's SVP of Finance, has assumed the roles of interim Principal Financial Officer and interim Principal Accounting Officer for SEC reporting purposes. The company has initiated a search for a CFO.
- 08/30/2024
|
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
- SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences:
- 08/28/2024
|
Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress
- A Phase 2 obesity and cardiometabolic trial of VTX3232 and a Phase 2a trial of VTX3232 in patients with Parkinson's disease are both expected to initiate in H2 2024
- 08/08/2024
|
Dow Edges Lower; Ventyx Biosciences Shares Plummet
- U.S. stocks were mostly higher toward the end of trading, while the Dow Jones index traded slightly lower on Monday.
- 07/29/2024
|
Ventyx Biosciences' Inflammatory Bowel Disease Candidate Flunks In Mid-Stage Study, Company Looks For Partner To Pursue It Further
- Ventyx Biosciences Inc VTYX stock is trading lower on Monday.
- 07/29/2024
|
VENTYX SHAREHOLDER ALERT: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Notified to Contact the Firm for Details
- NEW YORK, NY / ACCESSWIRE / June 25, 2024 / Top law firm Bleichmar Fonti & Auld LLP is investigating Ventyx Biosciences's (Nasdaq:VTYX) Board for Insider Trading. If you are a shareholder of Ventyx, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation.
- 06/25/2024
|
VENTYX STOCK ALERT: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Encouraged to Contact the Firm for Details
- NEW YORK, June 25, 2024 (GLOBE NEWSWIRE) -- Top law firm Bleichmar Fonti & Auld LLP is investigating Ventyx Biosciences's (Nasdaq:VTYX) Board for Insider Trading. If you are a shareholder of Ventyx, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation.
- 06/25/2024
|
VENTYX INVESTOR UPDATE: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Urged to Contact the Firm for Details
- NEW YORK, NY / ACCESSWIRE / June 24, 2024 / Top law firm Bleichmar Fonti & Auld LLP is investigating Ventyx Biosciences's (Nasdaq:VTYX) Board for Insider Trading. If you are a shareholder of Ventyx, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation.
- 06/24/2024
|
VENTYX INVESTOR ALERT: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Encouraged to Contact the Firm for Details
- NEW YORK, June 22, 2024 (GLOBE NEWSWIRE) -- Top law firm Bleichmar Fonti & Auld LLP is investigating Ventyx Biosciences's (Nasdaq:VTYX) Board for Insider Trading. If you are a shareholder of Ventyx, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation.
- 06/22/2024
|
VENTYX INVESTOR NOTICE: Ventyx's (NASDAQ:VTYX) Board is Being Investigated for Insider Trading Allegations, Long-term Investors Are Urged to Contact the Firm for Details
- NEW YORK, NY / ACCESSWIRE / June 21, 2024 / Top law firm Bleichmar Fonti & Auld LLP is investigating Ventyx Biosciences's (NASDAQ:VTYX) Board for Insider Trading. If you are a shareholder of Ventyx, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation.
- 06/21/2024
|
VENTYX SHAREHOLDER ALERT: BFA Law is Investigating the Ventyx (Nasdaq:VTYX) Board for Trading on Inside Information to Avoid Losses, Contact the Firm for Details
- NEW YORK, NY / ACCESSWIRE / June 20, 2024 / Top law firm Bleichmar Fonti & Auld LLP is investigating Ventyx Biosciences's (Nasdaq:VTYX) Board for Insider Trading. If you are a shareholder of Ventyx, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation.
- 06/20/2024
|
VENTYX INVESTOR REMINDER: Ventyx (Nasdaq:VTYX) Shareholders are Urged to Contact BFA Law about its Review of the Board's Insider Trading Scheme
- NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- If you are a shareholder of Ventyx Biosciences (NASDAQ: VTYX), you are encouraged to submit your information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation . Why is Ventyx Being Investigated by BFA?
- 06/20/2024
|
VENTYX INVESTIGATION REMINDER: Ventyx (Nasdaq:VTYX) Investors are Urged to Contact BFA Law about Inquiry into the Board for its Insider Trading Scheme and Avoiding Losses
- NEW YORK, NY / ACCESSWIRE / June 19, 2024 / If you are a shareholder of Ventyx Biosciences (NASDAQ:VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
- 06/19/2024
|
VENTYX INSIDER TRADING INQUIRY: Ventyx (VTYX) Shareholders are Urged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Losses
- NEW YORK, NY / ACCESSWIRE / June 18, 2024 / If you are a shareholder of Ventyx Biosciences (Nasdaq:VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
- 06/18/2024
|
VENTYX INSIDER TRADING ALERT: Ventyx (Nasdaq:VTYX) Shareholders are Urged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Losses
- NEW YORK, June 18, 2024 (GLOBE NEWSWIRE) -- If you are a shareholder of Ventyx Biosciences (NASDAQ: VTYX), you are encouraged to submit your information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation . Why is Ventyx Being Investigated by BFA?
- 06/18/2024
|
VENTYX NOTIFICATION: Ventyx (VTYX) Shareholders are Encouraged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses
- NEW YORK, NY / ACCESSWIRE / June 17, 2024 / If you are a shareholder of Ventyx Biosciences (Nasdaq:VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
- 06/17/2024
|
VENTYX INVESTOR ALERT: Ventyx (VTYX) Shareholders are Urged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses
- If you are a shareholder of Ventyx Biosciences (Nasdaq:VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
- 06/14/2024
|
BFA Law Notice: Ventyx (Nasdaq: VTYX) Shareholders are Encouraged to Contact the Firm about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses
- NEW YORK, NY / ACCESSWIRE / June 13, 2024 / If you are a shareholder of Ventyx Biosciences (Nasdaq:VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
- 06/13/2024
|
VENTYX REMINDER: BFA Law is Investigating Ventyx (Nasdaq: VTYX) Directors for Insider Trading Scheme and Avoiding Substantial Losses, Shareholders are Urged to Contact the Firm
- NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- If you are a shareholder of Ventyx Biosciences (NASDAQ: VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
- 06/13/2024
|
STOCK DROP NOTICE: Ventyx (Nasdaq:VTYX) Stock Drops 20%, Investors are Encouraged to Contact BFA Law about the Investigation into the Company's Board for Insider Trading
- NEW YORK, NY / ACCESSWIRE / June 12, 2024 / If you are a shareholder of Ventyx Biosciences (Nasdaq: VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
- 06/12/2024
|
VENTYX STOCK NOTICE: Ventyx (Nasdaq:VTYX) Stock Drops 20%, Shareholders are Reminded to Contact BFA Law about the Investigation into the Company's Board of Directors
- NEW YORK, NY / ACCESSWIRE / June 11, 2024 / If you are a shareholder of Ventyx Biosciences (Nasdaq:VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
- 06/11/2024
|
VENTYX INVESTIGATION ANNOUNCEMENT: Ventyx (Nasdaq: VTYX) Stock Drops 20%, Investors are Urged to Contact BFA Law about the Investigation into the Company's Board
- NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- If you are a shareholder of Ventyx Biosciences (NASDAQ: VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
- 06/11/2024
|
VENTYX NEWS NOTICE: Ventyx (Nasdaq: VTYX) Shareholders are Urged to Contact BFA Law about the Investigation into the Company's Board of Directors
- NEW YORK, June 08, 2024 (GLOBE NEWSWIRE) -- If you are a shareholder of Ventyx Biosciences (NASDAQ: VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below.
- 06/08/2024
|
VENTYX STOCK DROP ALERT: Ventyx (Nasdaq:VTYX) Directors Being Investigated for Insider Trading Scheme and Avoiding Substantial Losses, Shareholders are Urged to Contact BFA Law About Your Rights
- NEW YORK, NY / ACCESSWIRE / June 7, 2024 / If you are a shareholder of Ventyx Biosciences (NASDAQ:VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below. Why is Ventyx Being Investigated by BFA?
- 06/07/2024
|
BREAKING VENTYX ALERT: Ventyx (Nasdaq: VTYX) Stock Declines 20%, Shareholders are Reminded to Contact BFA Law about the Investigation into the Company's Board of Directors
- NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- If you are a shareholder of Ventyx Biosciences (NASDAQ: VTYX), you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/ventyx-biosciences-inc-investigation or contacting us below.
- 06/06/2024
|
Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers
- VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice
- 06/05/2024
|
VENTYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ventyx Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
- NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Ventyx Biosciences, Inc. (NASDAQ: VTYX) on behalf of long-term stockholders following a class action complaint that was filed against Ventyx on March 1, 2024 with a Class Period pursuant and/or traceable to the Offering Documents (defined below) issued in connection with the Company's initial public offering conducted on or about October 21, 2021 (the “IPO” or “Offering”); and/or (b) from October 21, 2021 to November 6, 2023. Our investigation concerns whether the board of directors of Ventyx have breached their fiduciary duties to the company.
- 06/03/2024
|
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
- SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences:
- 05/16/2024
|
Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer
- SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced the appointment of industry veteran Matthew Moore as Chief Operating Officer.
- 05/16/2024
|
Ventyx Biosciences, Inc. (VTYX) Q1 2024 Earnings Call Transcript
- Ventyx Biosciences, Inc. (NASDAQ:VTYX ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Martin Auster - Chief Financial Officer Raju Mohan - Founder and Chief Executive Officer John Nuss - Chief Scientific Officer Conference Call Participants Liam Hiester - Piper Sandler Emily Bodnar - H.C. Wainwright Gospel Enyindah-Asonye - Morgan Stanley Alex Thompson - Stifel Derek Archila - Wells Fargo Sam Slutsky - Life Science Operator Good afternoon, ladies and gentlemen and welcome to the Ventyx Biosciences First Quarter 2024 Earnings Conference Call.
- 05/11/2024
|
Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024
- SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the first quarter ended March 31, 2024 after market close on May 9, 2024. Company management will host a conference call and webcast beginning at 4:30 p.m. ET/ 1:30 p.m. PT that day to discuss the financial results and highlight recent pipeline and business progress.
- 05/02/2024
|
April 30, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against VTYX
- NEW YORK, NY / ACCESSWIRE / April 30, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=77625&wire=1 or contact Joseph E. Levi, Esq.
- 04/30/2024
|
VTYX DEADLINE TODAY: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class Action - VTYX
- NEW YORK , April 30, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ventyx Biosciences, Inc. (NASDAQ: VTYX): (i) pursuant and/or traceable to the offering documents issued in connection with the Company's October 21, 2021 initial public offering (the "IPO" or "Offering"); and/or securities (ii) between October 21, 2021 and November 6, 2023, both dates inclusive (the "Class Period"), of the important April 30, 2024 lead plaintiff deadline. SO WHAT: If you purchased Ventyx securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 04/30/2024
|
What Makes Ventyx Biosciences (VTYX) a New Buy Stock
- Ventyx Biosciences (VTYX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 04/30/2024
|
Class Action Filed Against Ventyx Biosciences, Inc. (VTYX) Seeking Recovery for Investors - Contact Levi & Korsinsky
- NEW YORK, NY / ACCESSWIRE / April 30, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=77617&wire=1 or contact Joseph E. Levi, Esq.
- 04/30/2024
|
Shareholders that lost money on Ventyx Biosciences, Inc.(VTYX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
- NEW YORK, NY / ACCESSWIRE / April 30, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=77602&wire=1 or contact Joseph E. Levi, Esq.
- 04/30/2024
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 30, 2024 in Ventyx Biosciences, Inc. Lawsuit - VTYX
- NEW YORK, NY / ACCESSWIRE / April 30, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=77589&wire=1 or contact Joseph E. Levi, Esq.
- 04/30/2024
|
FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / April 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ventyx Biosciences, Inc. ("Ventyx" or "the Company") (NASDAQ:VTYX) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's Offering Documents in connection with its initial public offering ("IPO") conducted on or about October 21, 2021 and/or between October 21, 2021 through November 6, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before April 30, 2024.
- 04/30/2024
|
Levi & Korsinsky Notifies Shareholders of Ventyx Biosciences, Inc. (VTYX) of a Class Action Lawsuit and an Upcoming Deadline
- NEW YORK, NY / ACCESSWIRE / April 30, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=77572&wire=1 or contact Joseph E. Levi, Esq.
- 04/30/2024
|
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 30, 2024 in Ventyx Lawsuit - VTYX
- NEW YORK, NY / ACCESSWIRE / April 30, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=77569&wire=1 or contact Joseph E. Levi, Esq.
- 04/30/2024
|
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Ventyx Biosciences, Inc. (VTYX)
- LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming April 30, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Ventyx Biosciences, Inc. (“Ventyx” or the “Company”) (NASDAQ: VTYX) investors who purchased: (a) common stock pursuant and/or traceable to the Company's October 2021 initial public offering (“IPO”); and/or (b) securities between October 21, 2021 and November 6, 2023, inclusive (the “.
- 04/29/2024
|
Levi & Korsinsky Reminds Ventyx Biosciences, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 30, 2024 - VTYX
- NEW YORK, NY / ACCESSWIRE / April 29, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=77523&wire=1 or contact Joseph E. Levi, Esq.
- 04/29/2024
|
VTYX DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class Action - VTYX
- NEW YORK, April 29, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ventyx Biosciences, Inc. (NASDAQ: VTYX): (i) pursuant and/or traceable to the offering documents issued in connection with the Company's October 21, 2021 initial public offering (the "IPO" or "Offering"); and/or securities (ii) between October 21, 2021 and November 6, 2023, both dates inclusive (the "Class Period"), of the important April 30, 2024 lead plaintiff deadline. SO WHAT: If you purchased Ventyx securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 04/29/2024
|
Contact Levi & Korsinsky by April 30, 2024 Deadline to Join Class Action Against Ventyx Biosciences, Inc.(VTYX)
- NEW YORK, NY / ACCESSWIRE / April 28, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=77423&wire=1 or contact Joseph E. Levi, Esq.
- 04/28/2024
|
Contact Levi & Korsinsky by April 30, 2024 Deadline to Join Class Action Against Ventyx Biosciences, Inc.(VTYX)
- NEW YORK, NY / ACCESSWIRE / April 28, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=77437&wire=1 or contact Joseph E. Levi, Esq.
- 04/28/2024
|
FINAL DEADLINE TUESDAY: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / April 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ventyx Biosciences, Inc. ("Ventyx" or "the Company") (NASDAQ:VTYX) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's Offering Documents in connection with its initial public offering ("IPO") conducted on or about October 21, 2021 and/or between October 21, 2021 through November 6, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before April 30, 2024.
- 04/28/2024
|
VTYX LAWSUIT ALERT: Levi & Korsinsky Notifies Ventyx Biosciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
- NEW YORK, NY / ACCESSWIRE / April 28, 2024 / If you suffered a loss on your Ventyx Biosciences, Inc. (NASDAQ:VTYX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ventyx-biosciences-inc-lawsuit-submission-form?prid=77407&wire=1 or contact Joseph E. Levi, Esq.
- 04/28/2024
|
FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm
- LOS ANGELES, CA / ACCESSWIRE / April 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Ventyx Biosciences, Inc. ("Ventyx" or "the Company") (NASDAQ:VTYX) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's Offering Documents in connection with its initial public offering ("IPO") conducted on or about October 21, 2021 and/or between October 21, 2021 through November 6, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before April 30, 2024.
- 04/28/2024
|
Down -86.57% in 4 Weeks, Here's Why Ventyx Biosciences, Inc. (VTYX) Looks Ripe for a Turnaround
- Ventyx Biosciences, Inc. (VTYX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
- 11/09/2023
|
Ventyx Biosciences Now Has 2 Strikes
- Today, we look at Ventyx Biosciences, Inc., a clinical-stage biopharma company focused on developing small molecule products for inflammatory diseases. The company has now had two major trial disappointments in the span of a month, triggering a huge selloff in the shares. However, the company's pipeline still has a few "shots on goal" and the stock is now trading below net cash on the balance sheet.
- 11/07/2023
|
Why Is Ventyx Biosciences (VTYX) Stock Down 76% Today?
- Ventyx Biosciences (NASDAQ: VTYX ) stock is falling hard on Tuesday after the clinical-stage biopharmaceutical company released poor study results. These results come from a Phase 2 clinical trial of VTX958 in patients suffering from moderate to severe plaque psoriasis.
- 11/07/2023
|
Ventyx Biosciences' stock suffering record plunge after psoriasis treatment trial fails to meet internal efficacy target
- Shares of Ventyx Biosciences Inc. VTYX, -9.56% plunged 73.7% in premarket trading Tuesday, after the biopharmaceutical company said it has decided not to support further development of its plaque psoriasis and psoriatic arthritis treatments. The stock, which was the biggest decliner listed on major U.S. exchanges ahead of the open, was on track to suffer a record one-day selloff and open in record-low territory.
- 11/07/2023
|
Ventyx (VTYX) Down Despite Positive Ulcerative Colitis Study Data
- Ventyx Biosciences (VTYX) announces positive top-line data from a phase II study evaluating its pipeline candidate, VTX002, for treating moderate-to-severely active ulcerative colitis. Stock down.
- 10/11/2023
|
Why Shares of Ventyx Biosciences Are Dropping Tuesday
- Ventyx is a clinical-stage biotech that focuses on autoimmune disorders. The company's lead therapy candidate is VTX002 to treat moderate-to-severe ulcerative colitis.
- 10/10/2023
|
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
- SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences:
- 08/30/2023
|
Ventyx Biosciences, Inc. (VTYX) Q2 2023 Earnings Call Transcript
- Start Time: 16:30 January 1, 0000 5:23 PM ET Ventyx Biosciences, Inc. (NASDAQ:VTYX ) Q2 2023 Earnings Conference Call August 10, 2023, 16:30 PM ET Company Participants Raju Mohan - Founder and CEO Marty Auster - CFO Bill Sandborn - President and Chief Medical Officer Conference Call Participants Michael Yee - Jefferies Alex Thompson - Stifel Vikram Purohit - Morgan Stanley Derek Archila - Wells Fargo Chris Shibutani - Goldman Sachs Emily Bodnar - H.C. Wainwright Sam Slutsky - LifeSci Capital Operator Good afternoon, ladies and gentlemen, and welcome to the Ventyx Biosciences Second Quarter 2023 Earnings Conference Call.
- 08/13/2023
|
Why Shares of Ventyx Biosciences Rose Monday
- Ventyx's shares shot up while insiders were selling. The company is a clinical-stage biotech.
- 07/03/2023
|
Ventyx: Critical Proof Of Concept Data Later This Year
- Ventyx Biosciences, Inc. has a number of interesting assets in mid-stage trials. The company is founded by a successful serial entrepreneur. Phase 2 data later this year will be pivotal for Ventyx Biosciences prospects.
- 06/15/2023
|
Ventyx Biosciences, Inc. (VTYX) Q1 2023 Earnings Call Transcript
- Ventyx Biosciences, Inc. (NASDAQ:VTYX ) Q1 2023 Earnings Conference Call May 11, 2023 6:00 PM ET Company Participants Raju Mohan - Founder & Chief Executive Officer Marty Auster - Chief Financial Officer Bill Sandborn - President & Chief Medical Officers Conference Call Participants Michael Yee - Jefferies Yasmeen Rahimi - Piper Sandler Derek Archila - Wells Fargo Alex Thompson - Stifel Chris Shibutani - Goldman Sachs Emily Bodnar - H.C. Wainwright Sam Slutsky - LifeSci Capital Operator Good afternoon, ladies and gentlemen, and welcome to the Ventyx Biosciences First Quarter 2023 Earnings Conference Call.
- 05/14/2023
|
Ventyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023
- ENCINITAS, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the first quarter ended March 31, 2023 after market close on May 11, 2023. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and highlight recent pipeline and business progress.
- 05/04/2023
|
Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names
- Where is the current bull market? All indications would be that it's in biotech!
- 04/20/2023
|
Ventyx Biosciences Stock Flals Over 4%: Details
- The stock price of Ventyx Biosciences Inc (NASDAQ: VTYX) fell by over 4% intraday today. This is why.
- 03/24/2023
|
Ventyx Biosciences to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
- ENCINITAS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference being held on March 30, 2023.
- 03/24/2023
|
Ventyx Biosciences, Inc. (VTYX) Q4 2022 Earnings Call Transcript
- Ventyx Biosciences, Inc. (NASDAQ:VTYX ) Q4 2022 Earnings Conference Call March 24, 2023 4:30 PM ET Company Participants Raju Mohan - Founder & Chief Executive Officer Marty Auster - Chief Financial Officer Bill Sandborn - President & Chief Medical Officers Conference Call Participants Michael Yee - Jefferies Yasmeen Rahimi - Piper Sandler Jeff Jones - Oppenheimer Chris Shibutani - Goldman Sachs Emily Bodnar - H.C. Wainwright & Co Operator Good afternoon, ladies and gentlemen, and welcome to the Ventyx Biosciences Fourth Quarter and Full Year 2022 Earnings Conference Call.
- 03/23/2023
|
Ventyx Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 23, 2023
- ENCINITAS, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the fourth quarter and full year 2022 after market close on March 23, 2023. Company management will host a conference call and webcast beginning at 4:30 p.m. ET/ 1:30 p.m. PT that day to discuss the financial results and highlight recent pipeline and business progress.
- 03/15/2023
|
Recent Price Trend in Ventyx Biosciences, Inc. (VTYX) is Your Friend, Here's Why
- Ventyx Biosciences, Inc. (VTYX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
- 02/27/2023
|
Ventyx Biosciences, Inc. (VTYX) Is a Great Choice for 'Trend' Investors, Here's Why
- Ventyx Biosciences, Inc. (VTYX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
- 02/10/2023
|
Are You Looking for a Top Momentum Pick? Why Ventyx Biosciences, Inc. (VTYX) is a Great Choice
- Does Ventyx Biosciences, Inc. (VTYX) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 02/03/2023
|
Here's Why Momentum in Ventyx Biosciences, Inc. (VTYX) Should Keep going
- Ventyx Biosciences, Inc. (VTYX) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
- 01/25/2023
|
Ventyx: Focusing On Competitive Differences Will Help
- Ventyx Biosciences, Inc. has three interesting molecules in inflammatory diseases. Each is in a different pathway validated by approved drugs.
- 01/13/2023
|
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
- ENCINITAS, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that Company executives will provide a company overview during fireside chats at the following upcoming investor conferences:
- 11/22/2022
|
Ventyx Biosciences, Inc. (VTYX) Q3 2022 Earnings Call Transcript
- Ventyx Biosciences, Inc. (NASDAQ:VTYX ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Marty Auster - Chief Financial Officer Raju Mohan - Founder & Chief Executive Officer Bill Sandborn - President & Chief Medical Officers Conference Call Participants Swapnil Malekar - Piper Sandler Sam Slutsky - LifeSci Capital Emily Bodnar - H.C. Wainwright Alex Thompson - Stifel Jeff Jones - Oppenheimer Operator Good afternoon, ladies and gentlemen, and welcome to the Ventyx Biosciences Third Quarter 2022 Earnings Conference Call.
- 11/06/2022
|
These Are the Five Best and Worst Performing Small-cap Stocks in September 2022
- Small-cap stocks are usually young companies that aspire to become large-cap or mega-cap one day.
- 10/21/2022
|
Bristol Myers Sotyktu Approval Sends Ventyx Stock Soaring: Consider Buying Both
- Big Pharma Bristol Myers Squibb won approval for plaque psoriasis therapy Sotyktu on September 9th - the drug may have $4bn peak sales potential. Ventyx has a drug with the same MoA entering a Phase 2 study. Phase 1 data suggests it could be superior to Sotyktu.
- 09/23/2022
|
Why Ventyx Biosciences Zoomed Nearly 60% Higher This Week
- The biotech benefits from a much larger peer's recent FDA approval.
- 09/16/2022
|
You can start to dip your toes into biotech here, says Jefferies' Yee
- Jefferies' Michael Yee joins 'Closing Bell' to discuss biotech stocks, which were one of the worst performers in today's sell-off. With CNBC's Michael Santoli.
- 09/02/2022
|
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
- ENCINITAS, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that Company executives will host investor meetings and provide a company overview during fireside chats at the following upcoming investor conferences:
- 08/29/2022
|
Ventyx Biosciences, Inc. (VTYX) CEO Raju Mohan on Q2 2022 Results - Earnings Call Transcript
- Ventyx Biosciences, Inc. (NASDAQ:VTYX ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Marty Auster - Chief Financial Officer Raju Mohan - Founder & Chief Executive Officer Bill Sandborn - President & Chief Medical Officers Conference Call Participants Yasmeen Rahimi - Piper Sandler Michael Yee - Jefferies Josh Schimmer - Evercore ISI Tiago Fauth - Credit Suisse Sam Slutsky - LifeSci Capital Jeff Jones - Oppenheimer Operator Thank you for standing by and welcome to the Ventyx Biosciences' Second Quarter 2022 Earnings Conference Call. At this time all participants are in listen only mode.
- 08/16/2022
|
Ventyx Biosciences' (VTYX) CEO Raju Mohan on Q1 2022 Results - Earnings Call Transcript
- Ventyx Biosciences, Inc. (NASDAQ:VTYX ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Marty Auster – Chief Financial Officer Raju Mohan – Founder and Chief Executive Officer Bill Sandborn – President and Chief Medical Officers Conference Call Participants Yasmeen Rahimi – Piper Sandler Josh Schimmer – Evercore ISI Michael Yee – Jefferies Tiago Fauth – Credit Suisse Sam Slutsky – LifeSci Capital Jeff Jones – Oppenheimer Operator Good day, and thank you for standing by. Welcome to the Ventyx Biosciences First Quarter 2022 Financial Results Conference Call.
- 05/13/2022
|
Ventyx Biosciences to Report First Quarter 2022 Financial Results on May 12, 2022
- ENCINITAS, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a range of inflammatory diseases with significant unmet medical need, today announced that it will report financial results for the first quarter ended March 31, 2022 after market close on May 12, 2022. Company management will host a conference call and webcast beginning at 4:30 p.m. ET/ 1:30 p.m. PT that day to discuss the financial results and highlight recent pipeline and business progress.
- 05/05/2022
|
Ventyx Biosciences to Participate in the Barclays Global Healthcare Conference
- ENCINITAS, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, announced today that Raju Mohan, Chief Executive Officer of Ventyx, will provide a company overview at the Barclays Global Healthcare Conference being held March 15-17, 2022.
- 03/07/2022
|
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences
- ENCINITAS, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, announced today that Raju Mohan, Chief Executive Officer of Ventyx, will provide a company overview at the following upcoming investor conferences:
- 11/19/2021
|
